Cd8 sk1 bv605 344741

Manufactured by BioLegend

The CD8 SK1 BV605 344741 is a fluorochrome-conjugated antibody that binds to the CD8 surface marker. It is designed for use in flow cytometry applications to identify and quantify CD8-positive cells.

Automatically generated - may contain errors

Lab products found in correlation

Pe cy7 369310, by BioLegend (4 mentions) Cd57 hcd57 fitc 322306, by BioLegend (4 mentions) Streptavidin apc 17 4317 82, by Thermo Fisher Scientific (3 mentions) 45ra hi100 apc cy7 304128, by BioLegend (3 mentions) Cd45ra hi100 apc cy7 304128, by BioLegend (3 mentions) Cd4 rpa t4 bv510 300545, by BioLegend (2 mentions) 4 rpa t4 bv510 300545, by BioLegend (2 mentions)

Spelling variants of this product

CD8-BV605 (11 citations) CD8 (SK1, (7 citations)

7 protocols using cd8 sk1 bv605 344741

Phenotypic Characterization of Engineered T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

AntibodyCloneFluorCatalogue #DilutionFor 1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-304128 (Biolegend)1:1001 uL

CY7

CCR7G043H7Pacific353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-821:1001 uL

(eBioscience)

This data shows that health of TRAC-/B2M-/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US10881689B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2021-01-05). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Phenotypic Characterization of Anti-CD19 CAR T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

For

AntibodyCloneFluorCatalogue #Dilution1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific 353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-82 1:1001 uL

(eBioscience)

This data shows that health of TRAC-/B2M-/anti-CD19+ CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US11166985B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2021-11-09). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Characterization of Engineered T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

Dilu-

AntibodyCloneFluorCatalogue #tionFor 1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-821:1001 uL

(eBioscience)

This data shows that health of TRAC−/B2M−/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US11622977B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2023-04-11). CRISPR THERAPEUTICS AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Characterization of Anti-CD19 CAR T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

For

AntibodyCloneFluorCatalogue #Dilution1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific 353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-82 1:1001 uL

(eBioscience)

This data shows that health of TRAC−/B2M−/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US11471491B1. Materials and methods for engineering cells and uses thereof in immuno-oncology (2022-10-18). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Anti-CD19 CAR T Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

AntibodyCloneFluorCatalogue #DilutionFor 1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

Strepta-APC17-4317-821:1001 uL

vidin(eBioscience)

This data shows that health of TRAC−/B2M−/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US11013767B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2021-05-25). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Anti-CD19 CAR T Cell Surface Marker Staining

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

For

AntibodyCloneFluorCatalogue #Dilution1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific 353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-82 1:1001 uL

(eBioscience)

This data shows that health of TRAC−/B2M−/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US11135247B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2021-10-05). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

Phenotypic Characterization of Engineered CAR T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 27

Allogenic anti-CD19 CAR T cells were generated as described above. At 21 days post gene editing, the following protocol was used to stain cells for expression of the indicated marker:

Stain cells with the following antibody for 30 min at 4° C.

Anti-mouse Fab2 biotin 115-065-006 (Jackson ImmunoRes) 1:5

Wash cells 1× with FACS buffer.

Add 1 μg of normal mouse IGG (Peprotech 500-M00) to 100 μL of cells for 10 min at RT.

Wash cells 1× with FACS buffer and resuspend in 100 μL of FACS buffer.

Stain cells with the following cocktail for 15 min at RT.

The antibodies used in this Example are as follows:

TABLE 29

Dilu-

AntibodyCloneFluorCatalogue #tionFor 1

CD4RPA-T4BV510300545 (Biolegend)1:1001 uL

CD8SK1BV605344741 (Biolegend)1:1001 uL

CD45RAHI100APC-CY7304128 (Biolegend)1:1001 uL

CCR7G043H7Pacific353210 (Biolegend)1:1001 uL

Blue

PD1EH12.2H7PE329906 (Biolegend)1:1001 uL

LAG311C3C65PE-Cy7369310 (Biolegend)1:1001 uL

CD57HCD57FITC322306 (Biolegend)1:1001 uL

StreptavidinAPC17-4317-821:1001 uL

(eBioscience)

This data shows that health of TRAC−/B2M−/anti-CD19+CAR T cells is maintained at day 21 post gene editing (the cells behave as normal (unedited) cells).

US10729725B2. Materials and methods for engineering cells and uses thereof in immuno-oncology (2020-08-04). CRISPR Therapeutics AG [CH]. Inventors: Jonathan Alexander Terrett [US], Demetrios Kalaitzidis [US], Lawrence Klein [US].

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!